Biogen Inc. (BMV:BIIB)

Mexico flag Mexico · Delayed Price · Currency is MXN
3,290.00
-54.00 (-1.61%)
At close: Nov 28, 2025
0.00%
Market Cap 483.91B
Revenue (ttm) 184.63B
Net Income (ttm) 29.50B
Shares Out n/a
EPS (ttm) 201.30
PE Ratio 16.40
Forward PE 13.86
Dividend n/a
Ex-Dividend Date n/a
Volume 36
Average Volume 285
Open 3,321.30
Previous Close 3,344.00
Day's Range 3,290.00 - 3,321.30
52-Week Range 2,395.00 - 3,356.00
Beta 0.15
RSI 67.55
Earnings Date Feb 12, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]

Sector Healthcare
Founded 1978
Employees 7,605
Stock Exchange Mexican Stock Exchange
Ticker Symbol BIIB
Full Company Profile

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD Financial Statements

News

There is no news available yet.